Ropes & Gray Aids TPG In $173M Chinese Pharma Buyout
An affiliate of TPG Capital LP has teamed with the chief executive of ShangPharma Corp., a China-based, U.S.-listed biomedical research group, to take the company private in a $173 million deal...To view the full article, register now.
Already a subscriber? Click here to view full article